Investigational Therapies and Ongoing Trials in ROS1+ NSCLC

Panelists explore the growing pipeline of investigational therapies that address limitations of currently approved ROS1 inhibitors. These include agents designed to overcome common resistance mutations and to provide improved brain penetration. Early clinical studies have demonstrated encouraging activity in patients who have progressed on prior targeted therapy.

They stress the importance of biomarker-driven clinical trial enrollment, which ensures appropriate matching between patient profiles and therapeutic targets. The development of next-generation inhibitors represents a critical step toward managing acquired resistance, which remains a major challenge in this disease subset.

The panel concludes that ongoing research efforts, including global collaborations, are critical for expanding the armamentarium against ROS1-positive lung cancer and ensuring continued progress toward durable disease control and improved patient outcomes.